Nascent founder and chief executive officer Dr. Mark C. Glassy and chief science officer Dr. Rishab K. Gupta have contributed a chapter to Humana Press’ new book “Human Monoclonal Antibodies: Methods and Protocols,” edited by Michael Steinitz. Glassy, M and Gupta, R. Technical and Ethical Limitations in Making Human Monoclonal Antibodies (an overview). In: Human […]
This author has yet to write their bio.Meanwhile lets just say that we are proud Nascent contributed a whooping 29 entries.
Entries by Nascent
Ft Lauderdale FL July 29, 2014 – Jin-En International Group Holding Co. (“Jin-en” or “the Company”) (PINK.BB: JINZ), is pleased to announce the acquisition 100% of the outstanding shares of Nascent Biologics, a Nevada corporation (“NBI”). As part of the acquisition, the Company has agreed to change its name to Nascent Biotech Inc. and plans […]
Please click to download the 2014 Cancer Facts and Figures PDF released by the American Cancer Society. In addition, please review this document, entitled “Cancer Statistics, 2011; The Impact of Eliminating Socioeconomic and Racial Disparities on Premature Cancer Deaths” in PDF format.
The Journal of Bioprocess Technology has published a paper co-authored by Nascent Biologics Inc. co-founder and chief executive officer Dr. Mark C. Glassy, PhD, entitled “Use of the GPEx® System to Increase Production of Pritumumab in a CHO Cell Line.” This study highlights NBI’s relationship with Catalent, detailed here. From the paper’s abstract: Expression of […]
Somerset, NJ, November 20 2012 – Dr. Greg Bleck, R&D Platform Director-Biologics, Catalent Pharma Solutions, will participate in a panel discussion titled “How collaboration can lead to faster pipeline progression”, on Wednesday 28th November at the European Antibody Congress 2012 (27 – 28 November 2012, Starling Geneva Hotel & Conference Center, Geneva, Switzerland). Part of […]
The following article appeared at Genetic Engineering & Biotechnology News on April 17, 2012: Catalent to Use Mammalian Cell Platform to Generate Nascent’s Anticancer Antibody Nascent Biologics signed an antibody development deal with Catalent Pharma Solutions through which the latter will use its GPEx® technology to engineer a cell line expressing Nascent’s pritumumab antibody for […]
SOMERSET, NJ, and SAN DIEGO, CA – April 16, 2012 — Nascent Biologics, Inc. and Catalent Pharma Solutions today announced the signing of a product development agreement. Under the terms of the agreement, Catalent will engineer a cell line expressing Nascent’s proprietary “Pritumumab” antibody using Catalent’s GPExÒ technology, and will subsequently produce purified monoclonal antibody […]
Nascent Biologics co-founder Mark C. Glassy has co-authored a new paper entitled “Summary analysis of the pre-clinical and clinical results of brain tumor patients treated with pritumumab.” Published in Human Antibodies 18, the paper covers the performance of pritumumab in patients with brain cancer. The bottom line: Pritumumab appears to be a safe and effective […]
SAN DIEGO – Mark Glassy, PhD, Chief Executive Officer and Co-founder of Nascent Biologics, Inc., (NBI), scientific researcher and inventor, announced today that he has recovered the license on his invention, “Pritumumab,” the first human antibody that has been used to treat cancer patients, after a 27 year absence in Japan. Dr. Glassy invented Pritumumab, […]